Free tool
FAERS Monitor: Sular
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020356 or its brand name (Sular, Nisoldipine). Reports on generic versions are filed under their own applications.
Reports
1,198
Serious
780
65% of reports
Hospitalization
394
Death reported
123
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- nausea89
- drug ineffective79
- dizziness77
- headache76
- fatigue74
- renal failure65
- pain64
- dyspnoea63
- asthenia62
- diarrhoea59
- anxiety54
- myocardial infarction54
- oedema peripheral54
- hypertension50
- pruritus50
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 58 |
| 2005 | 49 |
| 2006 | 82 |
| 2007 | 70 |
| 2008 | 81 |
| 2009 | 106 |
| 2010 | 111 |
| 2011 | 83 |
| 2012 | 85 |
| 2013 | 40 |
| 2014 | 54 |
| 2015 | 55 |
| 2016 | 51 |
| 2017 | 45 |
| 2018 | 58 |
| 2019 | 65 |
| 2020 | 28 |
| 2021 | 21 |
| 2022 | 15 |
| 2023 | 9 |
| 2024 | 15 |
| 2025 | 10 |
| 2026 | 7 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,961 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| renal failureSignal | 65 | 8.6 | 6.8 | 431 |
| oedema peripheralSignal | 54 | 7.8 | 6.0 | 314 |
| myocardial infarctionSignal | 54 | 5.4 | 4.2 | 193 |
| hypertensionSignal | 50 | 4.1 | 3.2 | 117 |
| anxietySignal | 54 | 3.3 | 2.6 | 87 |
| astheniaSignal | 62 | 2.9 | 2.3 | 76 |
| dizzinessSignal | 77 | 2.7 | 2.2 | 83 |
| pruritusSignal | 50 | 2.3 | 1.7 | 35 |
| headacheSignal | 76 | 2.1 | 1.7 | 46 |
| nausea | 89 | 2.0 | 1.6 | 43 |
| dyspnoea | 63 | 2.0 | 1.5 | 29 |
| pain | 64 | 1.8 | 1.4 | 24 |
| fatigue | 74 | 1.7 | 1.3 | 20 |
| diarrhoea | 59 | 1.6 | 1.3 | 13 |
| drug ineffective | 79 | 1.1 | 0.9 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.